Skip to content
Library/For Energy/EPO (Erythropoietin)
FDA Approved⚠ WADA Banned✓ Free to read

EPO (Erythropoietin)

Also called Epogen / Procrit / Aranesp

The hormone your kidneys use to make red blood cells, turned into a medicine for anemia, and famous as the original blood-doping drug.

Updated 03 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A copy of a hormone that makes red blood cells
Is it FDA-approved?
Yes, for anemia from kidney disease or chemo
How strong is the proof?
Very strong for sick patients. Dangerous for healthy people
How you take it
A shot, with a doctor watching your blood
Typical result
Fixes anemia so you stop needing blood transfusions
Biggest catch
Can cause deadly blood clots. Banned in sports

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

EPO is short for erythropoietin. It is a hormone your kidneys make. It tells your bone marrow to build red blood cells. Red blood cells carry oxygen around your body.

The medicine is a lab-made copy of that hormone. You may see the brand names Epogen, Procrit, or Aranesp. It has been since 1989.

Doctors give it to people who are very low on red blood cells. That low state is called anemia. When you are anemic, you feel tired and weak.

This is not an anti-aging or recovery . It is a serious medicine for sick patients.

What people use it for.

Doctors mainly use EPO for two groups of people.

  • People with bad kidney disease. Sick kidneys stop making enough EPO on their own, so they get anemic.
  • People going through chemo. Chemo can drop red blood cell counts.

There is also a dark side. Some athletes use it to cheat. More red blood cells means more oxygen, which can help endurance sports. This is illegal doping, and it has killed people.

Does it actually work?

Yes. In its real medical use, it works very well.

A landmark study back in 1987 showed it fixed the anemia of kidney failure. People no longer needed blood transfusions. EPO has been used in kidney and cancer care for over 30 years.

The question was never whether it works. The question is the cost to your heart. If you push your blood count too high, your blood gets thick. Thick blood clots more easily.

For healthy people chasing sports gains, the danger is not worth it. Athletes have died from it.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

EPO is the ultimate endurance booster.

true

It is the most proven endurance drug there is. The entire pro-cycling doping era ran on it. That is exactly what makes it deadly: the extra red cells that carry more oxygen also thicken your blood until it clots, and athletes have died doing this.

Micro-dosing keeps it safe.

no

There is no safe DIY dose. EPO carries the FDA's strongest warning for clots, heart attacks, and strokes, and the risk climbs as your blood count rises. Doctors keep kidney patients below a normal level on purpose for that reason.

You can buy it research-grade like other peptides.

no

EPO is a complex biologic, not a simple . There is no real research-only market, and the overseas listings are usually counterfeit. That gray route is the one tied to athlete deaths.

It's just a cheater's drug.

not quite

For anemia from kidney disease or chemo it is proven, medicine that ended the era of constant blood transfusions. The doping use is the dark side of a real drug, not the whole story.

How you take it.

You take EPO as a shot, but only with a doctor running the whole thing.

A doctor checks your blood often. For kidney patients, the goal is a hemoglobin of about 10–11 g/dL. That is kept on purpose below a healthy person's level so the blood does not get clot-thick. Aiming for a normal number pushes clot risk too high.

EPO also needs raw materials to work. Your body needs enough iron, B12, and folate to actually build red cells. If those are low, EPO can look like it "stopped working." It did not. The factory just ran out of supplies. A good doctor checks your iron before giving more.

What to watch out for.

The serious stuff

EPO carries the FDA's strongest warning. It is called a black box warning.

  • It can cause dangerous blood clots, heart attacks, and strokes. This is worse when your blood count is pushed too high.
  • It can make some cancers grow faster.
  • Used in sports, it has been linked to athlete deaths.

The honest version

EPO does exactly what it says. It raises your red blood cells. That is also what makes it risky. More red cells means thicker blood. Thicker blood clots. Your body has limits.

This is not a to self-experiment with. If you have real anemia, a kidney doctor should run it. We are not your doctor.

Where people get it.

Here are the ways people get EPO, from safest to riskiest.

  • Brand from a pharmacy (Epogen, Procrit, Aranesp). A real medicine you get with a prescription. This is the only safe way. It runs about $300–$1,500 a month, usually billed to insurance.
  • . Not possible. EPO is a complex biologic drug, not a simple . Special pharmacies cannot legally make it.
  • Research-only (). There is no real market for it either. Listings that exist are usually fake or repackaged.
  • overseas. The riskiest by far. Often counterfeit. This is the route tied to athlete deaths. Stay away.

The bottom line: if you do not have a real medical reason and a doctor, there is no safe way to buy this.

Our honest take.

Before this drug existed, kidney-failure patients lived permanently wiped out, tied to regular blood transfusions just to function. EPO ended that. It tells your marrow to build red cells, and the bone-deep exhaustion of anemia lifts. If you have anemia from kidney disease or chemo, this is proven, life-changing medicine. Run it with a kidney doctor who watches your blood and stocks your iron, B12, and folate first so the factory has supplies to work with.

The one hard line is sport. We would not touch EPO for endurance. The same red-cell boost that saves a dialysis patient thickens a healthy athlete's blood until it clots, and people have died doing exactly this. It is also the original banned doping drug, so a tested athlete gets caught.

And the practical wall: with no real medical reason and no doctor, there is no safe way to buy it. That is the whole verdict.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01LANGE RD, et al. ERYTHROPOIETIN. Progress in hematology. 1964;4:72-96. PMID: 14274541.
  2. 02GRISMONDI GL. [ERYTHROPOIETIN]. Attualita di ostetricia e ginecologia. 1964;10:959-75. PMID: 14305334.
  3. 03ACHESON ED. ERYTHROPOIETIN. British medical journal. 1964;1(5390):1060-1. PMID: 14113813.
  4. 04BUSOVA B. [ERYTHROPOIETIN]. Lekarsky obzor. 1964;13:113-20. PMID: 14126344.
  5. 05GOELTNER E. [ERYTHROPOIETIN IN PREGNANCY AND AFTER LABOR]. Archiv fur Gynakologie. 1964;200:60-87. PMID: 14299427.
  6. 06Ehrenreich H, et al. Erythropoietin in Preterm Infants. The New England journal of medicine. 2020;382(19):1862. PMID: 32374968.
  7. 07Mariotti C, et al. Erythropoietin in Friedreich ataxia. Journal of neurochemistry. 2013;126 Suppl 1:80-7. PMID: 23859343.
  8. 08Adamson J. Erythropoietin, iron metabolism, and red blood cell production. Seminars in hematology. 1996;33(2 Suppl 2):5-7; discussion 8-9. PMID: 8723573.
  9. 09SACKS MS. Erythropoietin. Annals of internal medicine. 1958;48(1):207-12. PMID: 13488231.
  10. 10Juul SE, et al. Erythropoietin in Preterm Infants. Reply. The New England journal of medicine. 2020;382(19):1862-1863. PMID: 32374969.
  11. 11Bieber E. Erythropoietin, the biology of erythropoiesis and epoetin alfa. An overview. The Journal of reproductive medicine. 2001;46(5 Suppl):521-30. PMID: 11396386.
  12. 12Aher SM, et al. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. The Cochrane database of systematic reviews. 2020;2(2):CD004865. PMID: 32048729.
  13. 13Zitella L. Erythropoietin-stimulating agents: new data yield new insights. Oncology (Williston Park, N.Y.). 2007;21(11 Suppl Nurse Ed):36-8. PMID: 18154208.
  14. 14ROSE JC. Erythropoietin. GP. 1958;17(1):81-2. PMID: 13490653.
  15. 15Jin X, et al. Erythropoietin alleviates lung ischemia-reperfusion injury by activating the FGF23/FGFR4/ERK signaling pathway. PeerJ. 2024;12:e17123. PMID: 38560469.
  16. 16DE RITIS G. [Erythropoietin]. Annali dell'Istituto "Carlo Forlanini". 1962;22:99-105. PMID: 13884489.
  17. 17MARINESCU S, et al. [Erythropoietin]. Medicina interna. 1961;13:1351-3. PMID: 14469874.
  18. 18Donadei C, et al. Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease. JCI insight. 2019;5(10). PMID: 31013255.
  19. 19Weiss MJ. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. The oncologist. 2003;8 Suppl 3:18-29. PMID: 14671225.
  20. 20Warrillow SJ. Erythropoietin use in the critically ill: current evidence. Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine. 2008;10(3):257-60. PMID: 18798726.
  21. 21Sfacteria A. Insights into erythropoietin in veterinary oncology: The other side of the coin. Veterinary journal (London, England : 1997). 2015;206(3):247-8. PMID: 26526865.
  22. 22Walker RG. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?. Clinical journal of the American Society of Nephrology : CJASN. 2008;3(4):935-7. PMID: 18579671.
  23. 23Yanagawa T, et al. Sufficient liver erythropoietin synthesis is induced in hemodialysis patients not requiring erythropoiesis-stimulating agents. Clinical nephrology. 2022;98(3):167-170. PMID: 35818816.
  24. 24ERSLEV AJ. THE ROLE OF ERYTHROPOIETIN IN THE CONTROL OF RED CELL PRODUCTION. Medicine. 1964;43:661-5. PMID: 14226581.
  25. 25Kaufman JS. Racial differences in erythropoietin responsiveness. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2008;52(6):1035-8. PMID: 19026356.
  26. 26Ford PA, et al. Strategies to optimize the use of erythropoietin and iron therapy in oncology patients. Transfusion. 2004;44(12 Suppl):15S-25S. PMID: 15585001.
  27. 27Feusner J, et al. Recombinant human erythropoietin in pediatric oncology: a review. Medical and pediatric oncology. 2002;39(4):463-8. PMID: 12203665.
  28. 28DA COSTA H, et al. Erythropoietin, current concept. Indian journal of medical sciences. 1963;17:132-7. PMID: 14024555.
  29. 29PLZAK LF Jr. Erythropoietin-a renal hormone. Surgical forum. 1960;10:121-4. PMID: 14433547.
  30. 30Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another. Current medical research and opinion. 2004;20(1):83-6. PMID: 14741076.
  31. 31EBIHARA T, et al. [ERYTHROPOIETIN--ERYTHROCYTE-STIMULATING FACTOR (2)]. Showa Igakkai zasshi = The Journal of the Showa Medical Association. 1963;23:323-9. PMID: 14157121.
  32. 32Peces R. [Pure red cell aplasia and antibodies against erythropoietin. Doubts still remain]. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia. 2003;23(4):295-6, 297. PMID: 14558327.
  33. 33Adamson JW, et al. Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Oncology. 1999;56(1):46-53. PMID: 9885377.
  34. 34De Luisi A, et al. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma. Angiogenesis. 2013;16(4):963-73. PMID: 23881169.
  35. 35MONTI G. [THE RENAL CONTROL OF HEMOPOIESIS: ERYTHROPOIETIN]. Il Policlinico. Sezione medica. 1963;70:307-23. PMID: 14119016.
  36. 36Edwards JK. Anaemia: Regulation of renal erythropoietin via HIF. Nature reviews. Nephrology. 2016;12(5):256. PMID: 26973079.
  37. 37WHITE WF, et al. Studies on erythropoietin. Recent progress in hormone research. 1960;16:219-62. PMID: 13844409.
  38. 38NAKAO K. Studies on erythropoietin. Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society. 1962;25:253-79. PMID: 13937478.
  39. 39GURNEY CW. Erythropoietin, erythropoiesis, and the kidney. JAMA. 1960;173:1828-9. PMID: 13830370.
  40. 40Bradbury J. Erythropoietin helps children with cancer-related anaemia. The Lancet. Oncology. 2006;7(9):713. PMID: 16981303.
  41. 41COTES PM. Erythropoietin and the physiological control of erythropoiesis. Proceedings of the Royal Society of Medicine. 1961;54(5):371-4. PMID: 13695858.
  42. 42Bejder J, et al. Detection of erythropoietin misuse by the Athlete Biological Passport combined with reticulocyte percentage. Drug testing and analysis. 2016;8(10):1049-1055. PMID: 27696774.
  43. 43RAMBACH WA, et al. The nature of erythropoietin. Annals of the New York Academy of Sciences. 1959;77:623-6. PMID: 14436017.
  44. 44MIRAND EA. ERYTHROPOIETIN STUDIES IN TAMARINS. Laboratory animal care. 1965;15:131-9. PMID: 14319534.
  45. 45D'Ambra MN, et al. Effect of recombinant human erythropoietin on transfusion risk in coronary bypass patients. The Annals of thoracic surgery. 1997;64(6):1686-93. PMID: 9436556.
  46. 46Macdougall IC. Biosimilar epoetins. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2009;24(5):1698-9; author reply 1699-700. PMID: 19366858.
  47. 47Guarienti M, et al. Computational and functional analysis of biopharmaceutical drugs in zebrafish: Erythropoietin as a test model. Pharmacological research. 2015;102:12-21. PMID: 26361727.
  48. 48LOWY PH, et al. Inactivation of erythropoietin by neuraminidase and by mild substitution reactions. Nature. 1960;185:102-3. PMID: 14418589.
  49. 49KELLER HM. [ERTHROPOIETIN]. Schweizerische medizinische Wochenschrift. 1964;94:1773-8. PMID: 14339495.
  50. 50GUTNISKY A, et al. STIMULATION OF ERYTHROPOIETIN PRODUCTION BY WHOLE-BODY IRRADIATION (SPLEEN SHIELDED). Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 1964;5:595-605. PMID: 14212185.
  51. 51FURUYA H. [Erythropoietin-endocrine regulation of hematopoiesis]. [Sanfujinka chiryo] Obstetrical and gynecological therapy. 1961;28:739-49. PMID: 13702709.
  52. 52ROSSE WF, et al. Renal cysts, erythropoietin and polycythemia. The American journal of medicine. 1963;34:76-81. PMID: 13975141.
  53. 53Banaei S, et al. Combination Anti-Apoptotic Effect of Erythropoietin and Melatonin on Ischemia Reperfusion-Induced Renal Injury in Rats. Acta medica Iranica. 2016;54(10):624-630. PMID: 27888589.
  54. 54Park SS, et al. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen. Journal of pharmaceutical sciences. 2009;98(5):1688-99. PMID: 18781649.
  55. 55Cowper B, et al. Glycan analysis of erythropoiesis-stimulating agents. Journal of pharmaceutical and biomedical analysis. 2020;180:113031. PMID: 31838284.
  56. 56Olsen NV. Central nervous system frontiers for the use of erythropoietin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2003;37 Suppl 4:S323-30. PMID: 14582001.
  57. 57DONATI RM, et al. NEPHROGENIC ERYTHROCYTOSIS. Archives of internal medicine. 1963;112:960-5. PMID: 14065007.
  58. 58 Counterfeit Procrit. FDA consumer. 2003;37(3):5. PMID: 12793379.
  59. 59Grampp G, et al. Structure-Function Relationships for Recombinant Erythropoietins: A Case Study From a Proposed Manufacturing Change With Implications for Erythropoietin Biosimilar Study Designs. Journal of pharmaceutical sciences. 2018;107(6):1512-1520. PMID: 29408510.
  60. 60ALTHOFF H. [ON THE CLINICAL SIGNIFICANCE OF ERYTHROPOIETIN]. Annales Nestle. [Deutsche Aufl.]. 1963;20:34-8. PMID: 14089326.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.